Cost drivers in the pharmacological treatment of interstitial lung disease

Cost drivers in the pharmacological treatment of interstitial lung disease

Abstract Introduction Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight economic burden of drug treatment in different ILD-subtypes we assessed cost tre...

Full description

Bibliographic Details
Main Authors: Phillen Nozibuyiso Maqhuzu, Michael Kreuter, Thomas Bahmer, Nicolas Kahn, Martin Claussen, Rolf Holle, Larissa Schwarzkopf
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Respiratory Research
Subjects:
Diffuse parenchymal lung disease
Healthcare expenditure
Direct costs
ILD management
Healthcare spending
Online Access:https://doi.org/10.1186/s12931-021-01807-8

Internet

https://doi.org/10.1186/s12931-021-01807-8

Similar Items